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Thrombocytopenia and pancytopenia, occurring in patients with Fanconi anemia (FA), are
interpreted either as progression to bone marrow failure or as developing myelodysplasia.
On the other hand, immune thrombocytopenia (ITP) represents an acquired and often
self-limiting benign hematologic disorder, associated with peripheral, immune-mediated,
platelet destruction requiring different management modalities than those used in congen-
ital bone marrow failure syndromes, including FA. Here, we describe the clinical course of
two independent FA patients with atypical – namely immune – thrombocytopenia. While
in one patient belonging to complementation group FA-A, the ITP started at 17months
of age and showed a chronically persisting course with severe purpura, responding well
to intravenous immunoglobulins (IVIG) and later also danazol, a synthetic androgen, the
other patient (of complementation group FA-D2) had a self-limiting course that resolved
after one administration of IVIG. No cytogenetic aberrations or bonemarrow abnormalities
other than FA-typical mild dysplasia were detected. Our data show that acute and
chronic ITP may occur in FA patients and impose individual diagnostic and therapeutic
challenges in this rare congenital bone marrow failure/tumor predisposition syndrome.
The management and a potential context of immune pathogenesis with the underlying
marrow disorder are discussed.
Keywords: immune thrombocytopenia, Fanconi anemia, bone marrow failure syndrome, DNA repair defect, Evans
syndrome, danazol, FANCA, FANCD2
Introduction
Thrombocytopenia and pancytopenia are frequent hematologic manifestations of Fanconi anemia
(FA) ascribed to a varying, increasing degree of congenital bone marrow failure and developing
myelodysplasia. Treatment options range from none (observation) to therapeutic administration of
androgens and, in case of transfusion dependence or signs of (pre-) malignancy, e.g., cytogenetic
aberrations indicative of clonal evolution, hematopoietic stem cell transplantation. At least 17 genes
are known to be involved in the pathogenesis of FA. Stringent genotype–phenotype correlations are
rare in classical FA and have consistently only been observed for variant groups, e.g., FA-D1 and
FA-N (1–3).
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Immune thrombocytopenia (ITP) is observed as an acquired
acute and self-limited benign post- or para-infectious or idio-
pathic cytopenia in otherwise healthy children that, if treat-
ment is required, usually responds well to high-dose intravenous
immunoglobulins (IVIG) and/or corticosteroids (4). Chronic ITP
may develop and indicate an underlying immune hematologic
disorder (5). Refractory chronic ITPwith bleeding diathesis some-
times requires additional immunosuppressive or thrombopoi-
etin agonist treatment, or splenectomy. We observed the clinical
course in two patients with thrombocytopenia of immune origin
in the context of FA. Here, we delineate the diagnostic and ther-
apeutic challenges of this previously unnoticed concurrence and
discuss potential implications.
Patients and Methods
Two patients who have been diagnosed, treated, and prospectively
monitored for FA at pediatric hematology/oncology departments
at the Medical University Graz and the Technische Universität
München (TUM) were found to suffer from ITP in 2014. The
data presented here were obtained by retrospective chart review.
Laboratory tests were performed according to clinical needs
and routine standard procedures. After mitomycin C-mediated
induction of G2 arrest and chromosomal breaks and/or comple-
mentation group analysis for FA, genetic testing was performed
by means of multiplex ligation-dependent probe amplification
(MLPA) and exon-scanning sequencing of genomic DNA of all
exons of FANCA (patient 1) and of FANCD2 (patient 2). Both
patients are registered within the German registry for FA FAR01
of the German Society for Paediatric Oncology and Haematology
(GPOH). The present study was performed upon informed con-
sent in accordance with Declaration of Helsinki and approval of
the responsible internal review boards.
Results
Patient Report 1
The first patient is a currently 3-year-old female, who was term-
born and small for gestational age. Additionally to intrauter-
ine growth retardation, other stigmata consistent with FA were
present (Table 1). Diagnosis was confirmed in vitro by typical
diepoxybutane- and mitomycin c-induced double strand break
induction, G2 arrest, and a FANCA mutation (EX2_6del het-
erozygous, second mutation yet elusive). Esophageal atresia type
IIIB required repetitive dilatation, until surgical intervention
(Nissen fundoplication) at 17months of age was undertaken.
Prior to surgery, peripheral blood counts were stable within
normal ranges. Baseline bone marrow evaluation had not been
performed. Postoperatively, an isolated mild thrombocytopenia
(minimum 70,000/µl) was observed. Platelet counts recovered
spontaneously to near normal ranges (>100,000/µl) within the
next months. A second abrupt and more pronounced platelet
decline (23,000/µl) along with generalized petechial exanthema
occurred 4months later following anesthesia for an esophageal
passage imaging study. Response to platelet transfusions was only
transitory (Figure 1A), and repeated platelet transfusions were
given to control the purpura. However, a brief increase of platelet
numbers was always followed by a rapid decline (Figure 1A). An
evaluation for allogeneic stem cell transplantation and a donor
search were initiated.
The early manifestation of thrombocytopenia in FA, refrac-
tory to administration of platelet concentrates, warranted a
more in-depth hematological evaluation. Apart from reduced
platelet numbers, peripheral blood counts and erythrocyte indices
remained normal during the period of observation (Table 1). Sur-
prisingly, bone marrow examination did not show bone marrow
failure or myelodysplastic syndrome (MDS; Table 1). In contrast,
it revealed a marrow of normal cellularity, a megakaryocyte count
in the upper normal range, and only mild dysplasia of all three
cell lines, considered “normal for FA”. Neither signs of malignant
infiltration and transformation to MDS were found, nor were any
clonal chromosomal aberrations such as 1q+, 3q+, 7/7q , 5/5q ,
or trisomy 8 detectable. In the absence of a clinically apparent
infection, PCR testing for HHV6, Parvovirus B19, CMV, and EBV
from the bone marrow aspirate were performed with negative
results. Assuming an immune-mediated mechanism IVIG were
given, leading to an increase of platelets. Subsequently, the throm-
bocytopenia demonstrated a chronically persisting course with
severe purpura, responding well to IVIG (Figure 1A). Anti-CMV
IgG (analyzed before IVIG administration) and IgMwere positive
in blood sample, as was CMV nucleic acid in the urine (4–6 104
copies/mL,Table 1), suggesting the presence of or recent recovery
from a CMV infection, which represents a potential trigger of
immune-mediated platelet destruction. The patient received a
total of three platelet transfusions and seven IVIG infusions (5
with 0.8 g/kg body weight and two infusions with 0.5 g/kg body
weight) within the first 6months after presentation with ITP, but
signs of bleeding (dry and wet purpura) and recurring thrombo-
cytopenia persisted (Figure 1A). A short attempt of corticosteroid
treatment with dexamethasone led to moderate response (platelet
increase from 24,000 to 91,000/µl) but was terminated by the
parents after 4 days because of inacceptable temper changes of the
girl. Treatment with danazol, a synthetic androgen, was initiated
at 5mg/kg/day 5months after the onset of thrombocytopenia,
which slowly led to a satisfactory responsewith regards to bleeding
tendency and was accompanied by a platelet count stabilization
between 40,000 and 140,000/µl. Thus, the need of interventional
IVIG treatment was substantially reduced (n= 2 per 6months
versus 7 per previous 6months; Figure 1A). Side effects of danazol
were weight gain (change of percentile from 10th to 25th within
9months) and mood swings, both considered unspecific and
tolerable for the patient by her family and treating physicians.
Virilization or other endocrine abnormalities were not observed
during the first 9months of danazol treatment. The androgen
dose could be reduced to 2mg/kg after 6months without change
of platelet counts and will be further reduced if platelet counts
remain stable. A recent follow-up bone marrow aspiration and
trephine biopsy 1-year after the initial manifestation of throm-
bocytopenia showed no dynamics as compared to the previous
analyses (not shown).
Patient Report 2
The second patient, a 7-year-old female was born on term with
intrauterine growth retardation and multiple congenital abnor-
malities typical for FA. Furthermore, she failed to thrive (Table 1).
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TABLE 1 | Patient characteristics of two girls with FA and ITP.
Patient 1 Patient 2
3 years, female 7 years, female
Genotype
FANCA compound heterozygous: EX2_6del; 2nd yet elusive FANCD2 compound heterozygous: 3-bp-deletion;
missense substitution at codon 815
Clinical presentation at birth and at diagnosis of FA
Pregnancy [week] 38+ 3 38+2
Birth weight [g] 2015 (<3rd%) 2280 (<10th%)
Birth length [cm] 44 (<3rd%) 46 (<10th%)
Head circumference [cm] 30.5 (<3rd%) 32 (10–25th%)
Upper limb
Thumb hypoplasia Right IIIa–b; left II Right
Thumb aplasia – Left
Lower limb
Congenital hip dysplasia – +
Head and face
Microcephaly  3SDe  3SD
Microphthalmia + +
Growth
Small stature  2SD  4SD
GI system
Esophageal atresia IIIb –
Cardiac system
Congenital heart defect – VSDf
Other
Impaired hearing + –
Hypogammaglobulinemia + (transiently) –
Blood type 0, Rh: positive 0, Rh: positive
Bone marrow at diagnosis of ITP Normocellular, discreet dysplasia and atypia of all
compartments; megakaryopoiesis numerically in the upper
normal range, 10% of megakaryocytes
mono-hypolobulated, no blasts
Moderately hypocellular, Blasts beneath 1%,
megakaryocytes without dysplasia, but clearly
reduced and with hyper-segmented nuclei
suspicious of MDS transformation
Patient 1 Patient 2
Complete blood counts
(selected parameters) Median (Min; Max) Median (Min; Max)
Hemoglobin [g/dl] 12.4 j (9.90; 14.8) 12.5 j (11.4; 13.7)
Reticulocytes [T/l] 0.081 j (0.042; 0.145) 0.04 j (0.02; 0.09)
Mean corpuscular volume [fl] 81.2 j (76.8; 93.2) 86.8 j (84; 91.8)
White blood cells [/µl] 6640 j (3850; 12400) 4600 j (2800; 7200)
Lymphocytes [/µl] 3800 j (1700; 7300) 4080 j (2260; 7310)
Neutrophil granulocytes [/µl] 2210 j (670; 8800) 1500 (1050; 3740)
Cellular immune system
CD3+ T cells [/µl] 3555 | normal j n.d.
CD3+CD4+ T cells [/µl] 2663 | normal j n.d.
CD3+CD8+ T cells [/µl] 635 | normal j n.d.
CD3–CD56+NK cells [/µl] 85 | moderately reduced n.d.
TRECs copies per 10e CD3+CD45+ 60500 | normal j n.d.
CD19+ B cells [/µl] 617 | normal j n.d.
TCRa/b+CD4–CD8–CD3+ <2% of T cells | normal n.d.
CD19+CD27+ IgD+ >2% of B cells | normal n.d.
CD19+CD27+ IgD  >2% of B cells | normal n.d.
Patient 1 Patient 2
Humoral immune system Age: 9/12 1 8/12 6 1/12
IgG [mg/dL] | low/normal/highg–i 177 | lowg 642 | normalh 1038 | normali
IgG1 [mg/dL] 121.49| lowg 498.28 | normalh n.a.a
(Continued)
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TABLE 1 | Continued
Patient 1 Patient 2
Age: 9/12 1 8/12 6 1/12
IgG2 [mg/dL] 34.41 | lowg 69.5 | normalh n.a.
IgG3 [mg/dL] 24.58 | normalg 73.83 | normalh n.a.
IgG4 [mg/dL] 0.66 | normalg 0.39 | normalh n.a.
IgA [mg/dL] 27.5 | normalg 54.3 | normalh 108 | normali
IgM [mg/dL] 50.9 | normalg 90.6 | normalh 44 | normali
IgE [IU/L] 4.2 | normalg n.d.b n.a.
Anti-diphtheria toxoid (DT) antibodies (Ab) [IU/L] 2.47 | normalg,c 2.37 | normalh,c n.d.
Anti-tetanus toxoid (TT) Ab [IU/L] 4.15 | normalg,c 2.48 | normalh,c n.d.
Anti-pneumococcus polysaccharide (PCP) Ab [mg/L] 42.96 |normalg,c 117.31 | normalh,c n.d.
Anti-Haemophilus influenza B polysaccharide (HIB) Ab [mg/L] 3.16 | normalg,c 5.1 | normalh,c n.d.
Autoantibodies at diagnosis of ITP
Coombs test direct Negative Negative
Anti-platelet antibodies Negative Positive:
GpIIb/IIIa
ANA Negative n.d.
Patient 1 Patient 2
Microbiological results at diagnosis of ITP
Anti-Parvo B19 IgM, IgG Negative Negative
Anti-CMV IgM Positive Negative
Anti-CMV IgG Positive Negative
Anti-EBV IgM, IgG Negative Negative
Anti-HHV6 IgM Negative Negative
Anti-HHV6 IgG Negative Positive
HIV antigen and antibody Negative Negative
Anti-HCV Negative Negative
Anti-HBs IgG Negativec Negative
Anti-HBc IgG Negative Negative
Anti-VZV IgM n.d. Negative
Anti-VZV IgG Negative Positive
Anti-measles IgG Positivec Positivec
Stool
Rotavirus AG ELISA n.d. Positive
Norovirus AG ELISA n.d. Negative
Adenovirs AG ELISA n.d. Negative
Urine
CMV nucleic acid 4–6104 n.d.
copies/mLl
Blood plasma nucleic acid detection
PCR for CMV; EBV; AdV; HSV1,2; HHV6, ParvoB19; VZV; Enterovirus Negative n.d.
an.a., data not available or not done before IVIG administration.
bn.d., not done.
cAfter vaccination.
eSD, standard deviation.
fVSD, ventricular septal defect l.
g–iAge-adjusted reference values.
g IgG: 223–1099; IgG1: 140–620; IgG2: 41–130; IgG3: 11–85; IgG4: 0–0,8; IgA: 1–73; IgM: 8–100; DT IgG: >1; TT IgG: 0,02–3,12; PCP IgG: 0,9–93; HIB IgG: 0,08–9,2.
h IgG: 344–1180; IgG1: 220–720; IgG2: 50–180; IgG3:14–91; IgG4: 0–40,8; IgA: 2–98; IgM: 12–104; DT IgG: >1; TT IgG: 0,04–3,92; PCP IgG: 0,9–29,2; HIB IgG: 0,16–40,8.
i IgG: 411–1435; IgA: 34–214; IgM: 15–115.
jNormal according to age-dependent reference ranges.
kAs described in the medical reports, precise data missing.
lAt three occasions within 9months.
Laboratory parameters in “bold” indicate pathologic results.
A compound heterozygous FANCD2 mutation confirmed the
diagnosis of FA (compound heterozygous for a 3-bp-deletion
and a missense substitution at codon 815) (6). Suddenly, at the
age of 6 years severe thrombocytopenia (13,000/µl) was observed
incidentally during a hospitalization for rotavirus gastroenteritis,
while the red and white blood counts remained stable. Other (e.g.,
myelosuppressive) viral infections were ruled out serologically
(Table 1). Similarly to the first patient, bone marrow aspiration
and a trephine biopsy were performed immediately to verify
suspected bone marrow failure, but no abnormalities other than
FA-typical mild dysplasia, nor any cytogenetic aberrations were
detected (Table 1). In the absence of myelosuppression ormarrow
failure, further evaluation was directed toward immune patho-
genesis of the low platelet count. Positive antiplatelet antibodies
against GpIIb/IIIa corroborated the diagnosis of ITP. Thrombocy-
topenia resolved after a single infusion of IVIG (Figure 1B), and
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A
FIGURE 1 | Platelet count and treatment of two girls with ITP and FA over time.
platelet counts remained stable thereafter during 1 year after the
initial presentation of ITP.
Discussion
The simultaneous occurrence of two diagnostic entities, that
have the potential to affect the platelet count through differ-
ent, apparently even reciprocal pathogenetic mechanisms, namely
ITP and FA, raised both diagnostic and therapeutic challenges.
While in one patient with a FANCA mutation, the ITP started
at 17months of age and showed a chronically persisting course
with severe purpura, that responded to IVIG and synthetic
androgen therapy, the other patient (with FANCD2 mutations)
had a self-limited course that resolved after a single adminis-
tration of IVIG. Other than FA-typical mild dysplasia, neither
bone marrow abnormalities nor cytogenetic aberrations were
detected. An association between platelet decline and anesthesia
cannot be excluded in patient 1, because thrombopenia initially
manifested shortly after gastroduodenoscopy in anesthesia. A
complete blood count had not been analyzed immediately before
general anesthesia.
Three possible interpretations for the concurrence of ITP and
FA may be discussed, which are pathogenetically relevant and
have implications for decisions of further treatment options.
First, the unusual combination of FA and ITP might be inter-
preted as coincidental – presuming that ITP developed inde-
pendently from the underlying FA. ITP occurs in 5 of 100,000
children per year, and FA is the most common inherited bone
marrow failure syndrome (IBMFS), frequently underdiagnosed
in patients without phenotypic abnormalities (7, 8). Addition-
ally, ITP may be associated with CMV infection as present in
the first patient (9, 10). Following this hypothesis, the ther-
apeutic approach to thrombocytopenia is supposed to adhere
to the general recommendations for treatment of ITP. Accord-
ingly, both reported patients demonstrate satisfactory response
to IVIG, known as first line therapeutic option for ITP (4).
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Although its effectiveness is largely attributed to immuno-
modulating activity and considered an indirect evidence for an
immune pathogenesis of an acute de novo thrombocytopenia, the
exact mechanism of action of IVIG in ITP is still not entirely
understood (11, 12). Interestingly, one study suggests a possi-
ble enhancement of thrombopoiesis by induction of endogenous
thrombopoietin production following IVIG administration (12).
Theoretically, in this case, platelet turnover might be positively
influenced by IVIG both in ITP and FA. Currently, data for the
efficacy of IVIG application in patients with FA are lacking. We
did not treat patient 1 with thrombopoietin receptor agonists,
because we generally aim to avoid hematopoietic growth factor
administration in tumor predisposition syndromes. Patients with
FA usually respond to treatment with androgens with an increase
of erythropoiesis and, to a lesser extent, also thrombopoiesis
(13–15). Likewise, a therapeutic efficacy of danazol is known in
chronic ITP and other autoimmune hematologic disorders (Evans
syndrome, autoimmune hemolytic anemia) (15–18). The exact
mechanism of action of synthetic androgens is unknown, but
immunomodulation is suspected to be involved (15).
Second, another explanation for the reported events could be
that the underlying stem cell impairment facilitated or induced
a subsequent immunologic reaction similar to that seen in
refractory cytopenia of childhood and severe aplastic anemia
(RCC/SAA) and thus, ITP might be considered “a feature of
FA.” In this case, bone marrow transplantation would have to be
considered an obvious therapeutic strategy like in MDS in FA
(19). Thrombocytopenia is a well-known first manifestation of
beginning bone marrow failure in FA (19), often associated with
macrocytosis and progessive myelodysplasia. However, macro-
cytosis was absent as was myelosuppression in bone marrow
analyses of both patients revealing normal cellularity, and even
megakaryocytosis in the first patient. Additionally, none of the
detected FA-associated gene mutations in our patients (FANCA
and FANCD2mutations) are typically linked to early transforma-
tion toMDS ormalignancy such as, e.g., FANC IVS5 in Ashkenazi
Jews, FANCD1/BRCA2, or FANCN mutations (20–24). Further-
more, patient 2 recovered soon after a single dose of IVIG, and
patient 1 repeatedly showed normalization of platelet numbers
upon IVIG, indicating a healthy regenerative capacity. Thus, MDS
or bone marrow failure was unlikely to be the cause of thrombo-
cytopenia seen in the presented FA patients aged 21months and
6 years.
Third, a more complex, multifactorial etiopathogenensis of
thrombocytopenia might be suspected in FA patients. A toxic
effect of preceding anesthesia in patient 1 and detected CMV
in patient 1 and Rotavirus in patient 2 or another undetected
viral infection triggering immunologic events might have more
pronounced effects in the setting of a “weak” bone marrow pre-
disposed toward dysplasia than in healthy bone marrow. While
MDS is usually unresponsive to IVIG, danazol is frequently used
to treat cytopenia in FA and Dyskeratosis congenita (19, 25).
Indirect evidence of immunoglobulin-supported remission of
thrombocytopenia in patient 2 and the good response of platelet
counts to IVIG (and later danazol) in patient 1, together with the
only mild, benign bone marrow abnormalities described, support
the hypothesis of an immune-mediated pathogenesis, but other
contributing factors facilitating thrombocytopenia such as those
mentioned cannot be excluded. Finally, in cannot be excluded that
the administration of unmatched platelet concentrates in patient
1 (given three times within a short time frame after her first drop
of platelet count) contributed to the immune pathogenesis and
persistence of thrombocytopenia.
There is no evidence that complementation group or position
or type of mutations in the present patients predisposed to ITP.
Exome sequencing in a larger series of FA patients with ITPmight
unveil second gene variants as a basis for the association of these
apparently coincidental clinical conditions.
Conclusion
Thrombocytopenia is a common event during the natural course
of FA. Because it is usually ascribed to bone marrow failure in FA,
occurrence of ITP in those patients might be missed or misin-
terpreted. Our data show that acute and chronic ITP may occur
in FA patients, and regular ITP-directed (IVIG) or “FA-adapted,
ITP-directed” treatment options (such as danazol) proved suc-
cessful. In contrast to current guidelines for the treatment of ITP
(4), we chose the synthetic androgen danazol for the long-term
treatment of chronically persisting ITP in a 2-year-old girl with
FA and observed good response with tolerable side effects. With
15months follow-up, we did not identify ITP as precursor ofMDS
in two pediatric FA patients.
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